ClinicalTrials.gg
Active, not recruitingNCT05043103ELEGANCEUpdated Oct 6, 2026

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

An observational study in Advanced Parkinson Disease, sponsored by Britannia Pharmaceuticals Ltd.. Active, not recruiting at 57 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Britannia Pharmaceuticals Ltd. · Observational

How we know

Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
312
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.

Enrollment
24th of 64
312 · median 195
Started
2021
with 10 others
Observational
64 of 264
19 open now
Primary completion
2026-10
later than 14 of 52 live
Registered
207th of 264
by date

Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 24th largest by enrollment of the 64 observational ones that give a count, is one of 11 that started in 2021, is one of 64 observational ones, reaches primary completion later than 14 of the 52 other live ones, and was the 207th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies in Parkinson Disease with a site in Germany, or all of them as a file.
02

Study summary

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

Read the detailed description

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients
03

Conditions studied

  • Advanced Parkinson Disease

Keywords

  • Parkinson´s Disease
  • Movement Disorders
  • Levodopa
  • Entacapone
  • Carbidopa Levodopa drug combination
  • Antiparkinson Agents
  • Anti-Dyskinesia-Agents
  • Dopamine Agents
  • Dopamine Agonists
  • Catechol-O-methyltransferase (COMT) inhibitor
  • Portable Pump
  • Gel
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Treating physician's normal patient pool

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving ) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion criteria

Exclusion Criteria:

  • Patients with as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
312 participants (actual)
Patient registry
No

Interventions

  • Combination productLecigon® based on European Medicines Agency (EMA) SmPC

    There might be different brand names in other countries

06

What researchers measure

Primary outcomes

  1. Change in OFF time from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

    Time frame: 24 months

  2. Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

    Time frame: 24 months

  3. Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose \[mg/day\] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

    Time frame: 24 months

  4. Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

    Time frame: 24 months

  5. Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

    Time frame: 24 months

  6. Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

    Time frame: 24 months

  7. Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation

    To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

    Time frame: 24 months

  8. Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation

    To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

    Time frame: 24 months

  9. Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation

    To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

    Time frame: 24 months

Secondary outcomes

  1. Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

    Time frame: 24 months

  2. Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation

    To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

    Time frame: 24 months

  3. Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

    Time frame: 24 months

  4. Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

    Time frame: 24 months

  5. Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

    Time frame: 24 months

Other outcomes

  1. Change in Body weight from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

    Time frame: 24 months

  2. Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

    Time frame: 24 months

  3. Change in Pulse from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

    Time frame: 24 months

  4. Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

    Time frame: 24 months

  5. Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

    Time frame: 24 months

  6. Change in the ECG from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

    Time frame: 24 months

  7. Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation

    To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

    Time frame: 24 months

07

Study locations

57 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Oct 2026, 63 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 63 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Sep 14, 2021
StartActual
Jul 6, 2021
Primary completionEst.
Oct 7, 2026was Sep 2026
CompletionEst.
Oct 7, 2026was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Oct 7, 2026
Oct 6, 2026
Study completion
Sep 2026→Oct 7, 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 2026→Oct 7, 2026
    Study completion Sep 2026→Oct 7, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05043103
Lead sponsor
Britannia Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Sep 14, 2021
Start date
Jul 6, 2021
Primary completion
Oct 7, 2026 (estimated)
Completion
Oct 7, 2026 (estimated)
Last update
Oct 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion